Joseph P. Gallant

This study engineers single-domain antibodies to improve targeting of FAP, showing that valency and molecular weight affect tumor uptake and biodistribution.

This paper develops a shark-derived VNAR-based theranostic agent for MET-altered NSCLC, showing imaging and therapeutic efficacy in preclinical models.

The paper develops FAP-targeted theranostics using VNARs from a shark antibody library, showing high affinity and efficacy in vitro and in vivo.

This study shows that swapping nanobodies at specific AAV capsid hotspots enables precise tropism switching for targeted gene therapy without extensive optimization.